Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China

Figures & data

Table 1 Baseline Characteristics of GT3 HCV Infected Cirrhosis

Parameter	GT3 HCV Cirrhosis (n=33)
Age (years) M ± SD	45.64±4.75
Male, n (%)	24 (72.7%)
Race, n (%)
Han	7 (21.2%)
Uygur	16 (48.5%)
Hui	9 (27.3%)
Kazakh	1 (3.0%)
HCV genotype, n (%)
3a	18 (54.6%)
3b	15 (45.4%)
Cirrhosis, n (%)
Compensated cirrhosis	16 (48.5%)
Decompensated cirrhosis	17 (51.5%)
Treatment regimen, n (%)
SOF/VEL	6 (18.2%)
SOF/VEL+RBV	27 (81.8%)
Course, n (%)
12 weeks	27 (81.8%)
24 weeks	6 (18.2%)
HCV RNA (log10 IU/mL) M ± SD	5.20±1.36

Abbreviations: GT, genotype; SOF/VEL, sofosbuvir/velpatasvir; RBV, ribavirin.

Table 2 Characteristics of 4 Virologic Failure Patients

Patient		Male1	Male2	Male3	Male4
HCV genotype		3b	3b	3b	3a
Regimen		SOF/VEL+RBV	SOF/VEL+RBV	SOF/VEL+RBV	SOF/VEL
Course (weeks)		12	12	12	24
SVR0		NO	YES	YES	NO
ALT (U/L)	Before treatment	87	66	45	53
	After treatment	45	46	34	39
CPT scores	Before treatment	8	14	5	8
	After treatment	7	8	5	7

Abbreviations: SOF/VEL, sofosbuvir/velpatasvir; RBV, ribavirin; SVR0, sustained virological response at the end of treatment; ALT, alanine transaminase; CPT, Child-Pugh-Turcotte.

Figure 1 (A) The SVR0 and SVR12 of GT3 HCV cirrhosis treated with SOF/VEL ± RBV. (B) The SVR12 of GT3 HCV compensated cirrhosis and decompensated cirrhosis treated with SOF/VEL ± RBV. (C) The SVR12 of GT3a HCV cirrhosis and GT3b HCV cirrhosis treated with SOF/VEL ± RBV. (D) The SVR12 of GT3 HCV cirrhosis treated with SOF/VEL ± RBV.

Table 3 Comparison of GT3 HCV Infected Cirrhosis Before and After Treatment

		After treatment				p
		CPT A	CPT B	CPT C	n
Before treatment	CPT A	17	0	0	17	0.003
	CPT B	6	4	0	10
	CPT C	2	2	2	6

Abbreviation: CPT, Child-Pugh-Turcotte.

Table 4 Comparison of GT3 HCV Decompensated Cirrhosis Before and After Treatment

		After Treatment				p
		CPT A	CPT B	CPT C	n
Before treatment	CPT A	1	0	0	1	0.003
	CPT B	6	4	0	10
	CPT C	2	2	2	6

Abbreviation: CPT, Child-Pugh-Turcotte.

Table 5 Comparison of GT3 HCV Cirrhosis and Decompensated Cirrhosis Before and After Treatment

Parameter	GT3 HCV Cirrhosis (n=33)		GT3 HCV Decompensated Cirrhosis (n=17)
	Before Treatment	After Treatment	Before Treatment	After Treatment
CPT scores M ± SD	7.12±2.40	5.85±1.50*	8.76±2.31	6.65±1.77**
Leukocytes (×10^9/L) M ± SD	4.83±1.68	4.92±1.65	4.58±2.01	4.36±1.80
Hemoglobins (g/L) M ± SD	130.03±32.18	154.03±117.77	111.53±33.37	160.94±165.76
Platelets (×10^9/L) M ± SD	96.51±44.78	100.67±43.87	89.65±47.78	89.82±46.93
Total bilirrubin (μmol/L) M ± SD	34.54±15.91	25.60±11.17**	41.99±17.03	30.45±12.88**
Albumin (g/L) M ± SD	34.30±7.01	36.17±6.03**	28.81±5.05	32.5±5.62**
ALT (U/L) M ± SD	86.12±72.56	31.13±13.33**	61.47±46.06	35.8±16.10*
PT (S) M ± SD	14.85±2.40	13.51±1.20**	16.08±2.57	14.76±1.88
Creatinine (μmol/L) M ± SD	62.79±10.86	62.77±10.32	62.95±11.84	61.44±12.12
Ascites, n (%)	8(24.2%)	3(9.1%)	8(47.1%)	3(17.6%)
HE, n (%)	8(24.2%)	1(3.0%)*	8(47.1%)	1(5.9%)*
EGVB, n (%)	3(9.09%)	1(3.0%)	3(17.7%)	1(5.9%)

Note: *P < 0.05, **P < 0.01.

Abbreviations: CPT, Child-Pugh-Turcotte; ALT, alanine transaminase; PT, plasma prothrombin time; HE, hepatic encephalopathy; EGVB, esophageal and gastric variceal bleeding.